3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Conditions
Breast Neoplasms
6
Colorectal Neoplasms
4
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Neoplasm Metastasis
2
Carcinoma, Non-Small-Cell Lung
2
Biliary Tract Neoplasms
2
Sarcoma
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Muscle Invasive Bladder Cancer (MIBC)
1
Metastatic HER2-positive Breast Cancer
1
Hemangiosarcoma
1
Head and Neck Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Adenocarcinoma Of Esophagus
1
Interventions
pembrolizumab
25
Cisplatin
17
Carboplatin
13
Radiotherapy
12
Cetuximab
9
Blood Specimen Collection
9
Docetaxel
8
Paclitaxel
7
Fluorouracil
7
Drug Therapy
7
toripalimab
6
tislelizumab
4
nimotuzumab
4
atezolizumab
4
Surveys and Questionnaires
4
Radiation
4
Chemoradiotherapy
4
fludarabine
3
Surgical Procedures, Operative
3
Standard of Care
3
Radiotherapy, Intensity-Modulated
3
Cyclophosphamide
3
Biopsy
3
130-nm albumin-bound paclitaxel
3
cemiplimab
2
avelumab
2
X-Rays
2
Tocopherols
2
Tiragolumab
2
Therapeutics
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Head and Neck Neoplasms
×
zanidatamab
×
Clear all
NCT07192068
2025-12-19
AcSé HER2
UNICANCER
Phase 2
Recruiting
105 enrolled